Liver cancer treatment study combining interventional and systemic therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are diagnosed with liver cancer (hepatocellular carcinoma/HCC) by biopsy or imaging.
- You have had or plan to have a combination of interventional treatment (e.g., TACE, HAIC, ablation) and systemic therapy (e.g., targeted therapy, immunotherapy).
- Your medical history and treatment records are available, and you can attend follow-up visits.
- You are willing to sign a consent form.
- Your liver function is not severely damaged (Child-Pugh class A or B, not C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.